- Home
- GDYN vs FULC Comparison
GDYN vs FULC Comparison
Compare GDYN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDYN | FULC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.0M | 718.4M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GDYN | FULC |
|---|---|---|
| Price | $7.25 | $8.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $11.00 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 1.6M | 915.0K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 350.00 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $111,283,000.00 | N/A |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $9.59 | N/A |
| P/E Ratio | $64.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.11 | $2.32 |
| 52 Week High | $19.11 | $15.74 |
Technical Indicators
Market Signals| Indicator | GDYN | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 37.55 |
| Support Level | $6.16 | $6.33 |
| Resistance Level | $8.43 | $8.50 |
| Average True Range (ATR) | 0.46 | 0.84 |
| MACD | 0.14 | -0.26 |
| Stochastic Oscillator | 91.32 | 18.40 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.